Evidence map›Paper›PMID 30208358›Full record

ArticleNuclear medicine and biology2018

Assessing the feasibility of intranasal radiotracer administration for in brain PET imaging.

Nisha Singh, Mattia Veronese, Jim O'Doherty, Teresa Sementa, Salvatore Bongarzone, Diana Cash, Camilla Simmons, Marco Arcolin, Paul K Marsden, Antony Gee and 1 more

Abstract read
In one paragraph

Article in Nuclear medicine and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Imaging of intranasal drug delivery to the brain.American journal of nuclear medicine and molecular imaging · 2020
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nisha SinghDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom; School Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom. Electronic address: Nisha.singh@kcl.ac.uk.
Mattia VeroneseDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom.
Jim O'DohertyPET Imaging Centre Facility, King's College London & Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, United Kingdom; Department of Molecular Imaging, Sidra Medicine, Doha, Qatar.
Teresa SementaSchool Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom.
Salvatore BongarzoneSchool Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom.
Diana CashDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom.
Camilla SimmonsDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom.
Marco ArcolinDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom.
Paul K MarsdenSchool Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom; PET Imaging Centre Facility, King's College London & Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, United Kingdom.
Antony GeeSchool Biomedical Engineering & Imaging Sciences, 4th floor Lambeth Wing, St Thomas' Hospital, King's College London, London SE1 7EH, United Kingdom; PET Imaging Centre Facility, King's College London & Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London SE1 7EH, United Kingdom.
Federico E TurkheimerDepartment of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, De Crespigny Park, London SE 5 8AF, United Kingdom.

Funding

Medical Research Council MR/K022733/1Wellcome Trust
6 · The paper itself

Abstract

introductionThe development of clinically useful tracers for PET imaging is enormously challenging and expensive. The intranasal (IN) route of administration is purported to be a viable route for delivering drugs to the brain but has, as yet, not been investigated for the delivery of PET tracers. If the intranasal (IN) pathway presents a viable option, it extends the PET imaging field by increasing the number of tracers available for human use. Here we report the results of a rodent study testing the feasibility of the IN route to administer radiotracers for brain PET imaging.

methodsWe used two different, well characterised, brain penetrant radiotracers, [

resultsContrary to our hypothesis, in case of both radiotracers, we did not see a higher ratio in the expected brain regions, except in the olfactory bulb, that is closest to the nose. It appears that the radiotracers move into the olfactory bulb region, but then do not progress further into other brain regions. Moreover, as the nasal cavity has a small surface area, the extrapolated dosimetry estimations for intranasal human imaging showed an unacceptably high level (15 mSv/MBq) of cumulative skin radiation exposure.

conclusionsTherefore, although an attractive route for brain permeation, we conclude that the intranasal route would present difficulties due to non-specific signal and radiation dosimetry considerations for brain PET imaging.

Indexed as

Administration, IntranasalAnimalsBenzamidesBrainFeasibility StudiesFluorodeoxyglucose F18HumansMaleOlfactory BulbPositron Emission Tomography Computed TomographyPyrrolidinesRadiochemistryRatsRats, Sprague-DawleyTissue DistributionBenzamidesFluorodeoxyglucose F18N-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamidePyrrolidinesBlood brain barrierBrain PET imagingIntranasalNeuroimagingNose-to-brain pathway

Identifiers

PMID30208358
PMCPMC6288068

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.